Method for producing dehydropyridines

专利摘要:
Dihydropyridines of the formula:- and their pharmaceutically acceptable acid addition salts; wherein R is an optionally substituted aryl or heteroaryl group; R' and R2 are each independently C1-C4 alkyl or 2-methoxyethyl; Y is -(CH2)n- where n is 2, 3 or 4 and is optionally substituted by 1 or 2 methyl groups; and R3 is an optionally substituted 5- or 6-membered heterocyclic group attached to the adjacent nitrogen atom by a carbon atom, said heterocyclic group being optionally fused to a further 5- or 6-membered heterocyclic group or to a benzene ring, said further heterocyclic group and benzene ring also being optionally substituted. The compounds are calcium antagonists useful as anti-ischaemic and antihypertensive agents.
公开号:SU1296006A3
申请号:SU833682597
申请日:1983-12-20
公开日:1987-03-07
发明作者:Фразер Кэмпбелл Симон；Эдвард Кросс Питер；Кендрик Стаббс Джон；Эдманд Арроусмит Джон
申请人:Пфайзер Корпорейшн (Фирма)；
IPC主号:

专利说明:

11296006
This invention relates to methods for preparing new heterocyclic compounds of the dihydropyridine series of the general formula
to k about and in in e nneu yu p n e n and t
H R., COOR
 CHjOCH CHgT HR °
where R is .phenyl, substituted once or twice by a chlorine atom or a trifluoromethyl group; R IR - each independently C -C-alkyl;
R is pyrimidinyl or pyrimidinyl, substituted C-C-alkyl, C, -C-alkoxy, phenyl, phen-OXY-, pyridyl-OXO-, amino OXI-, cyano-, carbamoyl groups or a halogen atom, puricyl; quinazolinyl or quinazolinyl, substituted oxo C, -C-alkoxy-, or amino groups; imidazolinyl substituted with oxo or alkyl groups; triazinip or aminotriazinil; pyridyl or pyridyl substituted by a carbamoyl group or a S02NR R group, where R and R are each independently hydrogen or methyl, or together with the nitrogen atom to which they are attached form piperidino, morpholino, 4-formylpiperazin-1-yl; thiazolyl, optionally substituted with M, N-dimethylsulfamidothiazolyl; benzthiazolyl; thiadiazolyl or its S-oxide ;, possibly substituted alkoxy; pyrazinyl or its N-oxide, possibly substituted by a halogen atom; quinoxalin or quinoxapin substituted by a halogen atom; pyrrolinyl; or triazolyl, possibly substituted amino, and their acid additive, pharmaceutically acceptable salts.
The aim of the invention is the development, on the basis of known methods, of a method for the preparation of new chemical compounds possessing a major anti-inflammatory and antihypertensive effect.
Example 1. 4- (2-Chlorophenyl) -3-Ztoxycarbonyl-5-methoxycarbonyl-6-methyl-2-12- (3,4-dihydro-4-oxopyri MIDIN-2-IL amino) -ethoxymethyl -1, 4 dihydropyridine.

2- (2-Aminoethoxymethyl) -3-ethoxycarbonyl-4- (2-chlorophenyl) -5-methoxycarbonyl-6-methyl-, 4-dihydropyridine (0.75 g) and 2-methylthio-ZN-pyrimide -4- (0.5 g) was dissolved in 5 ml of ethanol and refluxed for 20 hours. The solvent was evaporated, the residue was partitioned between ethyl acetate and water. The organic layer is separated, washed with 2N. hydrochloric acid to remove unreacted amine, and then dilute sodium hydroxide solution. It is then washed with water, dried, filtered and evaporated, resulting in a yellow resin. After chromatography on silica gel Kiesel-gel (trade mark), eluting with ethyl acetate, the title compound of the example is obtained which is crystallized from ethyl acetate. Yield 171 mg (18%) so pl. 148-150 C.
Calculated,%; N 11.15.
S ,, H, S IN, Oh,
C 57.3; H 5.4;

Found,%: C 57.3; H 5.55; N 11.4.
Examples 2-29. The compounds of these examples; get analogously to example I; their characteristics are given in the table.
Examples 30-50. These compounds were prepared according to the procedure of Example I, starting from 2- (2-aminostoxy-methyl) -3-ethoxycarbonyl-4- {2,3-dichlorophenyl} -5-methoxycarbonyl-6-metsh1-1,4-dihydropyridine


n, c n
compounds 30-50
Examples 51-56. These compounds were as described in Example 1, starting from 2- (2-aminoethoxymethyl) -3-ethoxycarbonyl-4- (2-chloro-3-trifluoromethylphenyl) -5-methoxycarbonyl-6-methyl-1,4 -dihydropyridine; ,
-Cl H: iCOOC x4 COOC2H5
1 i n HjC -NHR
compounds 51-56 Example 57. 3- {2- 4- (2,3-Dichlorophenyl) -3-ethoxycicarbonyl-5-methoxycarb6-nyl-6-methyl-1,4-dihydropyrid-2-yl methoxyethylamino A- methoxy-
1, 2,5-tiadeol -} - oxide,
2- (2-Aminoethoxymethyl) -3-ethoxycarbonyl-4- (2,3-dichlorophenyl) -5-methyroxycarbonyl-6-methyl-1,4-dihydropyridine (0.5 g) and 3, 4-dimethoxy-1,2, 5-thiadiazole-1-oxide (0.2 g) is dissolved in methanol (15 ml) and refluxed for 14 hours. The solvent is evaporated and the residue is chromatographed on silica gel. Zelgel Bon (trade mark), eluted with ethyl acetate. The fractions containing the product are combined and evaporated to give an oil, which upon trituration in ethyl acetate gives the target compound of the example, yield 0.14 g, 10%, mp. 183-85 p.
Calculated,%: C, 48.15; H 4.55; N 9.75.
.
Found,%: C 48; H 4.6; N 9.4.
P j) and meper 58; Compound with mp 158-160 ° C is prepared in a manner similar to the previous example, starting from the corresponding 4- (2-chlorophenyl) -1,4-dihydropyridine and 3,4-dimethoxy-1, 2, 5-thiadiazole-1-oxide. The reaction time is 18 h, the solvent is methanol, yield 24%:
C1
.ooC2H5

H
Calculated,%: C, 51.25; H 5.0; .N 10.4.
0.5
Found,%: C 52.0; H 5.4; N 10.1.
Example 59, Connection with so pl. 139-141 s get by the method.
similar to example 57, starting from the corresponding 4- (2-chloro-3-trifluoromethylphenyl) - 1,4-dihydropyridine and 3,4-dimethoxy-1,2,5-thiadiazole-1-oxide. The reaction time is 18 h, the solvent is methanol, yield 83%:
ten
CHjOOC
Ochi
Calculated,%: C, 47.5; H 4.3; N 9.2,
Found,%: C 47.3; H 4.4; N 9.4.
Example 60. This compound was prepared analogously to example 57, starting from the corresponding 4- (2,3-dichlorophenyl) -, 4-dihydropyridine:

} / CHJCOOCjHs
1N.ES
C1
C1
COOCzHg.j
CH OlCHjb-if - ij-4jH, H
20 25 t
35
45
55
50
t, pl, 195-196 ° C.
Found,%: C 52.2; H 5.35; N 15.6
C., H ,, Cl, N 05-1 / i “CH, SOOS, H,
Calculated,%: C 50.45; H 5.15; 15.35.
Examples 61-66. These compounds were prepared according to the procedure of Example 1, starting from 2- (2-aminoethoxymethyl) -3-methoxycarbonyl-4- (2,3-dichlorophenyl) -5-toxycarbonyl-6-methyl-1,4-dihydropyridine :
 C1
HgCaOOCvjXX COOCHj
N. N
compounds 61-66 Example 67, 4- (2-Chloro-3-trifluoromethyl) -3-toxycarbonyl-5-methoxycarbonyl-6-methyl-2- (2-GN- - (4-amino-6,7-dimethoxyquinazoline- 2il) amino ethoxymethyl) pyridine:
-CF
-1,4-dihydro
SNS
  and H
A mixture of 4 (2-chloro-3-trifluoromethyl) -3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-2- (2-aminoethoxy) methyl-1,4-dihydropyridine (0.48 g) 4-amino-2 -chloro-6,7-dimethoxyquinazoline (0.24 g), 4-dimethylaminopyridine (0.12 g) and n-butanol (Yu ml) was heated under reflux with stirring for 18 h, Raster evaporated, and the residue divided between 2 and. a solution of hydrochloric acid and ethyl acetate. The organic layer was sequentially washed with water, concentrated ammonia solution and water, and then dried with anhydrous sodium sulfate. The solution was evaporated, and the residue was separated by chromatography on silica gel. The column was diluted with ethyl acetate and the polarity of the eluant was gradually increased by adding up to 5% methanol. The impurities were first eluted, and then the pure product. The product, containing the fractions, was hydrated, and the residue was crystallized from a mixture of ethyl acetate and petroleum ether (t, bale 60-80 ° C) to form the desired one. Compounds of Example solvated with 0.25 molar equivalents of ethyl acetate. Output 0.08 g, t, pl. 186-187 ° C
Found,%: C 54.92; H 5.03; 9.97,
N
C ,, N, 0,,
0.25,
Calculated,%: C 54.81; H 4.88; N 9.99.
Pharmacological testing. The ability of compounds to inhibit calcium transport into cells has been demonstrated by their effectiveness in reducing the response of isolated cardiac tissue to increasing calcium ion concentrations in vitro. The test procedure consists in fixing helically cut strips of a rat aorta from one end and attaching the other end to a force transducer. The tissue is immersed in a bath with physiologists.
saline solutions containing potassium ions in a concentration of 45 mmol and not containing calcium. Calcium chloride is added to the bath with a pipette in such quantity that the final concentration of calcium ions is 2 mmol. The change in tension caused by the contraction of the tissue is noted, the bath is drained and replaced; - with fresh saline and after 45 The min test is repeated with the particular compound tested in saline. The concentration of the compound required to reduce the response by 50% (C) is recorded. Activity data The following are molar concentrations of the compounds that are necessary to reduce the reaction by 50% in the indicated tests. The lower the concentration, the more active the compound.
Example Compound
I
2 3 4 5 6 7
eight
9 10
eleven
12 13 14 15 16 17
1C
50
1.05
1, 2640 M
1M
4.2640 M 2.8840 ® M 6.3 "10 M 1.040 M
5.01 10- "M
1.0040 M 1, 31 40 M
3.16.10 m 1.0040 M 1, M 1.0040 M 1, 8240 M 1, 0040 M 1, 0010 M
coronary vessels were calculated by means of the division of arterial blood pressure by coronary flow.
In order to investigate the duration of action of some compounds, intravenous doses were given that could cause approximately 60% of the maximum coronary expansion, and the time needed to achieve a peak effect on the resistance of the coronary vessels was recorded so as to reduce it by 50%. % The following results were obtained:
example connection
ifedipine 1
2
30 31 32 34 35 38 47 62
Duration of action, h
5-10 min
. 25 min
one
6 h 5 h 3.5 h 6-7 4
1 1/4 1 3/4 3-4

权利要求:
Claims (1)
[1]
1. A method of producing dihydropyridines of the general formula
H R R OOC COOR2
I ii
W; SN, OCH ,, 1} VD
Ns ii
where R is phenyl substituted one or two times by a chlorine atom or a trifluoromethyl group;
R and R are each independently C, - Cc alkyl;
5 o
five
0
five
0
five
0
five
0
five
R- is pyrimidinyl or pyrimidinyl substituted with C, -C-alkyl. C, alkoxy, phenyl, phenoxy, pyridyl, OXO, amino, OXY, cyano, carbamoyl groups or halogen atom; puercil; quinazolinyl or quinazolinyl, substituted by oxo-, C-C-apkoxy-, or amino groups; imidazolinyl substituted with oxo or C, -C-alkyl groups; triazinyl or aminotriazinyl; pyridyl or pyridyl substituted with a carbamoyl group or group. SO. wherein R and R are each independently hydrogen or methyl, or together with the nitrogen atom to which they are attached form piperidino, morpholino, 4-formylpiperazin-1-yl; thiazolyl, possibly substituted by N, L-dimethylsulfamidothiazolyl; benzthiazolyl; thiadiazolyl or its S-oxide, possibly substituted - alkoxy; pyrazinyl or its N-oxide, possibly substituted by a halogen atom; quinoxaline or quinoxaline substituted by a halogen atom; pyrrolinyl; or triazolyl, possibly substituted amino, their acid addition, pharmaceutically pharmaceutically, salts of salts, characterized in that the compound of the general formula
H R
L С HjC CHjOCHsCHgl Hg
where R, R and R have the indicated meanings, are reacted with a compound of the general formula
R Q,
where R has the indicated meanings, Q is the group NHNO, j, C, -C-alkyl. C, -C-alkoxy or halogen,
with the subsequent allocation of the target product in the form of bases or in the form of acid addition, pharmaceutically acceptable salts.
2, the method according to claim 1, wherein the process is carried out in the presence of a base such as trietstamide, sodium carbonate or 4-dimethylaminopyridine in the case when Q is methylthio or chlorine.
about
vO
With vO
oh oh
X
about
D
; z5
 Wvt 0 «7
I o
about
uh m
cl
I o
3 CD I
Cl
about
3 OQ
Cl
M
D
; z5
1L
vO
o
"T
m
a
n
1L warhead
-in in
0
tn
40 v
ate
"L
I “o
o j -
CO
I 1Л
oi i. GI
o I o
"L l
in
t.
tn I - m I in
fs
in
about
in
 n
in I
G1 I 00
. j.
r in
CO
in
in l
in in
in
in
in r
o t o
in I in
CHO G
about f
(l r i o

about
I 1Л
I 1
| H
I 1G |
Mo “i.
in I "l
1L
n
- J with
1L
sh
"L I 1L W I 1L
SP
"L
 Yu
1 p
fv.
t
ABOUT
1L
oo
about
about
"
ON
I "about
with
u-i
"
P
1Л, Ч I € Ч
"L I in
P I ate
about
I 1O
I in
00 I OO Yu i Sh
"L I" about I sh
vO
about hch
about
"L
he
o (h
OO
(ABOUT
g
 im g
00
"about
l
"
he
Xx
OO
OO
00
-
Ui
U
sh
S
"J
Ui
$
I
BUT
"but
N
V V t T
t
MF
K2
to sc
00 "h
"O I -"
 I
with I "about
o i i i «G
r "M
I
4IG4
“O
t -
& &
00
o.
about
z
z I
I
I
00
YU
"
00
I e (
I 00
o
-
00
 ft
4f
- I -
 I tf i fl
“O
O i r.
VO
1L
"
P
o
1L
- I ts
m I 1Л
one
go
in
MF
PI
§
"N
s
CM
00
rx
1L
1 f.
w
M
Oh
OO
OO
CO
ca
3 OQ
about
g
about
z
about
Yu
and Vf
li ".
h w
five-("
Q
s
iri en
vO n
r "
l
and
I
I 1
t
"
in
in
cr o
I
about
0) 4)
OSM
cttd
on
Yuo
about
ma
uo
lO
i-i
Sh
w
Sh
"Chim
I
"LIm
inI1L
if i o
CO
in
CO
in
 I.
in I m
fO
I o
about "n
$ 1
ABOUT
n
fl) w
OS
H
0)
Om
oo
stand by
mu
oo
01
m
he
I ii
W
z 1a
S9is
You
I 3o
- hX
about
W
er
(P
about
J.
to
MF
-
m
j -. i o
about - I about
oh f -
I Ш
I
(st
Yu I iri
- I
I About I III
IT,
a
in
about
1L
in
r m
/
Sh
§
v Ы
rn I
I L «T (
I 04
I
I on
“G i -. J OFC
PTS
ABOUT
you r
“Oo oh - oh.
R. I
(A0 I
GI O
in i oh
I "oo I" l
t I
I in1Л I
о I о 1 I. o
in I in in I in
r I 00
"I
 I sf
r
"L
fIr
one
COI00
"L}" n
n "o
in f in y-I in
tn i vo
in I n
in. O n
l
r
tM
oo t
I
-
S
&
“O
PTS
n
z
n
§
tM
"
m
he
14
M
Sh
w u
00
S
$
about
“A I
I 3
 s:
five
§
: ao
PTS
m

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1296006A3|1987-03-07|Method for producing dehydropyridines

---

US4628098A|1986-12-09|2-[2-pyridylmethylthio-|]benzimidazoles

---

AU598491B2|1990-06-28|Pyridyl-methylthio substituted benzimidazoles

---

EP0071819B2|1992-06-10|Dihydropyridines with a positive inotropic activity, their use in pharmaceutical preparations, and processes for their preparation

---

SU1279528A3|1986-12-23|Method of producing 1,4-dihydropyridines or hydrochlorides thereof

---

DE2935451A1|1981-03-19|OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT

---

DE3331808A1|1984-03-08|CARBOSTYRIL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM

---

DE3522579C2|1995-10-12|Novel 1,4-dihydropyridine derivatives and salts thereof, processes for their preparation and pharmaceutical compositions containing the same

---

PL185099B1|2003-02-28|Shortly acting dihydropyridines

---

EP0172029B1|1991-02-27|1,4-dihydropyridines

---

US4139623A|1979-02-13|Cyclic-substituted derivatives of 1-amino-2-propanol

---

US4127574A|1978-11-28|4-Hydroxy-3-sulfonyl-quinolin-2|-ones

---

DE19842833B4|2005-04-14|2-Arylalkylthio-imidazoles, 2-Arylalkenylthio-imidazoles and 2-Arylalkinylthio-imidazole as anti-inflammatory and inhibitors of cytokine release

---

CA1245654A|1988-11-29|Process for preparing novel n-substituted derivatives of 1-|-2-amino-1,3-propanediol

---

EP0105702B1|1986-06-25|Dioxocyclobutene compounds

---

EP0233760A1|1987-08-26|Sulfenamide derivatives and their production

---

EP0353238A1|1990-02-07|New intermediate products and process

---

CA1094073A|1981-01-20|N-carbonylamino-tetrahydropyridyl derivatives

---

EP0095104A2|1983-11-30|Process for the preparation of pyridyl and quinolyl imidazolinones

---

US4355166A|1982-10-19|Quinuclidinic ester and derivatives of phenoxycarboxylic acids

---

JP2678786B2|1997-11-17|1,4-dihydropyridine derivative

---

EP0302871A1|1989-02-15|1,4-Dihydropyridines

---

US4920230A|1990-04-24|Method of producing nitrogen-containing heteroaromatic compounds having an alkoxy group

---

US4567276A|1986-01-28|β-Adrenergic 2-[4-|phenyl]imidazoles

---

SU1303025A3|1987-04-07|Method for producing derivatives of 1,4-dihydropyridine

同族专利:

---

公开号 | 公开日

---

IL70477D0|1984-03-30|

---

JPS59118782A|1984-07-09|

---

NO159272B|1988-09-05|

---

DK586583D0|1983-12-20|

---

JPH0225913B2|1990-06-06|

---

PL140573B1|1987-05-30|

---

NZ206614A|1986-05-09|

---

ES528157A0|1985-08-01|

---

CA1215050A|1986-12-09|

---

NO834689L|1984-06-22|

---

NO159272C|1988-12-14|

---

EP0116769A1|1984-08-29|

---

KR840006968A|1984-12-04|

---

PL245158A1|1985-05-07|

---

PH20114A|1986-09-29|

---

ES8506633A1|1985-08-01|

---

YU246883A|1986-06-30|

---

PT77842B|1986-05-05|

---

AU2255983A|1984-06-28|

---

FI834692A|1984-06-22|

---

PT77842A|1984-01-01|

---

DK586583A|1984-07-27|

---

DD213920A5|1984-09-26|

---

US4661485A|1987-04-28|

---

CS249516B2|1987-03-12|

---

GR81351B|1984-12-11|

---

HU193275B|1987-09-28|

---

AT26114T|1987-04-15|

---

FI79104B|1989-07-31|

---

ZA839381B|1985-08-28|

---

US4670449A|1987-06-02|

---

YU175585A|1986-06-30|

---

SU1391499A3|1988-04-23|

---

KR860001921B1|1986-10-25|

---

FI79104C|1989-11-10|

---

PL140069B1|1987-03-31|

---

ES8505997A1|1985-06-16|

---

AU546057B2|1985-08-15|

---

FI834692A0|1983-12-20|

---

PL250215A1|1985-07-16|

---

IL70477A|1987-08-31|

---

EP0116769B1|1987-03-25|

---

ES534723A0|1985-06-16|

---

US4572908A|1986-02-25|

---

DE3370481D1|1987-04-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4284634A|1975-07-02|1981-08-18|Fujisawa Pharmaceutical Co., Ltd.|1,4-Dihydropyridine derivatives, and pharmaceutical method of the same|

---

DE2658183A1|1976-12-22|1978-07-06|Bayer Ag|2-POSITION SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS A MEDICINAL PRODUCT|

---

US4177278A|1977-04-05|1979-12-04|Bayer Aktiengesellschaft|2-Alkyleneaminodihydropyridines compounds, their production and their medicinal use|

---

DE2740080A1|1977-09-06|1979-03-15|Bayer Ag|2-Aminoalkyl-1,4-di:hydro-pyridine derivs. - with broad spectrum of effects on the heart and circulation, e.g. lowering blood pressure and spasmolytic effect|

---

US4144343A|1978-01-04|1979-03-13|Merck & Co., Inc.|Heterocycle substituted pyridines|

---

JPS5547656A|1978-09-29|1980-04-04|Dainippon Pharmaceut Co Ltd|2--1,4-dihydropyridine derivative and its derivative|

---

DE2844595A1|1978-10-13|1980-04-30|Bayer Ag|2-Acylamino:alkyl-di:hydro-pyridine derivs. - useful as cardiovascular agents acting as coronary dilators, hypotensives, antiarrhythmics, vascular spasmolytics and hypolipaemics|

---

SE7910521L|1979-12-20|1981-06-21|Haessle Ab|NEW 2-METHYL-6-SUBSTITUTED-4- -1,4-DIHYDROPYRIDINE-3,5-DIESTERS WITH HYPOTHESIVE PROPERTIES, AND PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATION|

---

DE3022030A1|1980-06-12|1981-12-17|Bayer Ag, 5090 Leverkusen|4-THIAZOLE or 4-IMIDAZOLE-SUBSTITUTED, 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THE MEDICINAL PRODUCTS CONTAINING THEM|

---

CS228917B2|1981-03-14|1984-05-14|Pfizer|Method of preparing substituted derivatives of 1,4-dihydropyridine|

---

DK161312C|1982-03-11|1991-12-09|Pfizer|CHANGES FOR THE PREPARATION FOR THE PREPARATION OF 2-Amino-CO-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-4-Methyl-2-D-Hydroxy|

---

EP0100189B1|1982-07-22|1986-05-28|Pfizer Limited|Dihydropyridine anti-ischaemic and antihypertensive agents|

---

EP0107293A3|1982-09-04|1984-06-06|Pfizer Limited|Dihydropyridines|

---

US4515799A|1983-02-02|1985-05-07|Pfizer Inc.|Dihydropyridine anti-ischaemic and antihypertensive agents|

---

JP5547656B2|2008-01-15|2014-07-16|ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー|Methods for manipulating phagocytosis mediated by CD47|EP0125803A3|1983-04-27|1987-01-21|FISONS plc|Pharmaceutically active dihydropyridines|

---

GB8331120D0|1983-11-22|1983-12-29|Pfizer Ltd|Benzaldehyde derivatives|

---

EP0164247B1|1984-06-07|1989-01-11|Pfizer Limited|Dihydropyridines|

---

GR851819B|1984-08-17|1985-11-26|Wyeth John & Brother Ltd|

---

US5202330A|1985-06-03|1993-04-13|E. R. Squibb & Sons, Inc.|2-thio or oxo-4-aryl or heterocyclo-1,5-pyrimidinedicarboxylic acid diesters and 3-acyl-5-pyrimidinecarboxylic acids and esters|

---

DE3531498A1|1985-09-04|1987-03-05|Bayer Ag|DIHYDROPYRIDIN-2-HYDROXYAMINE, METHOD FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS|

---

GB8601382D0|1986-01-21|1986-02-26|Pfizer Ltd|Dihydropyridine antiischaemic & antihypertensive agents|

---

IT1204421B|1986-06-27|1989-03-01|Boehringer Biochemia Srl|2-METHYL-1,4-DIHYDROPYRIDINE, A METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

US4820842A|1986-11-19|1989-04-11|Warner-Lambert Company|2-substituted-1,4-dihydropyridines|

---

IT1204948B|1987-03-13|1989-03-10|Boheringer Biochemia Robin S P|2-THYOMETHY-SUBSTITUTE-PYRIDINS, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.|

---

US4753946A|1987-04-08|1988-06-28|E. R. Squibb & Sons, Inc.|Pyrimidinecarboxylic acid derivatives|

---

GB9319341D0|1993-09-17|1993-11-03|Wellcome Found|Novel process|

---

GB9611046D0|1996-05-25|1996-07-31|Wivenhoe Techn Ltd|Pharmacological compounds|

---

ES2151850B1|1998-10-26|2001-08-16|Esteve Quimica Sa|INTERMEDIATE FOR THE SYNTHESIS OF AMLODIPINO FOR ITS OBTAINING AND CORRESPONDING USE.|

---

CZ20031779A3|2000-12-29|2004-10-13|Bioorganicsáb@V|Process for preparing amlodipine, its derivatives and precursors thereof|

---

US6653481B2|2000-12-29|2003-11-25|Synthon Bv|Process for making amlodipine|

---

CA2433193C|2000-12-29|2006-01-31|Pfizer Limited|Amide derivative of amlodipine|

---

PL376405A1|2002-10-07|2005-12-27|Artesian Therapeutics, Inc.|Dihydropyridine compounds having simultaneous ability to block l-type calcium channels and to inhibit phosphodiesterase type 3 activity|

---

EP1975167A1|2007-03-30|2008-10-01|Esteve Quimica, S.A.|Acetone solvate of phthaloyl amlodipine|

---

JP2010100562A|2008-10-23|2010-05-06|Daito Kk|Method for purifying intermediate for producing amlodipine|

---

CN102464608B|2010-11-15|2016-05-11|江苏先声药物研究有限公司|Compound and as L-type calcium channel blocker or/and the application of acetylcholinesteraseinhibitors inhibitors|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB8236347|1982-12-21|

---